Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs
- 21 June 2023
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 77, 104840
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Report of Three Cases of Herpes Zoster During Treatment with NatalizumabCNS Neuroscience & Therapeutics, 2013
- Immunosuppression and Chagas Disease: A Management ChallengePLOS Neglected Tropical Diseases, 2013
- Pharmacodynamic Effects of Steady‐State Fingolimod on Antibody Response in Healthy Volunteers: A 4‐Week, Randomized, Placebo‐Controlled, Parallel‐Group, Multiple‐Dose StudyThe Journal of Clinical Pharmacology, 2012
- Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology, 2011
- SEVERE CUTANEOUS CANDIDA INFECTION DURING NATALIZUMAB THERAPY IN MULTIPLE SCLEROSISNeurology, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patientsMultiple Sclerosis Journal, 2009
- GLANCENeurology, 2009
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996